New insight into the management of IgA nephropathy

Letter to the editor



This work was supported by grants from Chinese Society of Nephrology (14050430580).

Compliance with ethical standards

Conflict of interest

No potential conflict of interest relevant to this letter was reported.


  1. 1.
    Lv J, Zhang H, Wong MG, et al; TESTING Study Group. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 2017;318(5): 432–42.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Rauen T, Eitner F, Fitzner C, et al. STOP-IgAN investigators. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373:2225–36.CrossRefPubMedGoogle Scholar
  3. 3.
    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013; 3(Suppl):1–150.Google Scholar
  4. 4.
    Yang M, Xu G, Ling L, et al. Performance of the creatinine and cystatin C-based equations for estimation of GFR in Chinese patients with chronic kidney disease. Clin Exp Nephrol. 2017;21(2):236–46.CrossRefPubMedGoogle Scholar
  5. 5.
    Bökenkamp A, Laarman CA, Braam KI, et al. Effect of corticosteroid therapy on low-molecular weight protein markers of kidney function. Clin Chem. 2007;53(12):2219–21.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2018

Authors and Affiliations

  1. 1.Outpatient DepartmentNanjing Medical UniversityNanjingChina
  2. 2.Division of Nephrology, Shanghai Fifth People’s HospitalFudan UniversityShanghaiChina
  3. 3.Department of Nephrology, Nanjing First HospitalNanjing Medical UniversityNanjingChina

Personalised recommendations